Researcher Stories

Drug Screening

Drug screening for new therapeutic targets

Aubin Michalon, PhD, Senior Research Scientist, Neurimmune Holding AG

Human tissue is essential for drug screening and analysis of the efficacy of potential new therapeutics. NDRI provides tissue to corporate researchers who use the biospecimens to complement in vitro and animal studies. Aubin Michalon, PhD, a project lead at Neurimmune Holding AG, is working to find novel therapeutics to treat disease.  Dr. Michalon’s studies are critical to improve patient care, especially in cases where current therapies only manage symptoms and do not slow disease progression.

“NDRI organized the collection of patient tissue samples that would have been extremely difficult to obtain otherwise, these samples have been essential for shaping the new therapeutics we are working on.”

Neurimmune uses recombinant human monoclonal antibodies to support development of immunotherapies for diseases such as Alzheimer’s disease and other dementias, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Type 2 diabetes.

 

NDRI is a Not-For-Profit (501c3) Corporation.